MRI预测晚期卵巢癌间歇性肿瘤细胞减灭术完全切除的多中心MISSION试验
该前瞻性多中心队列研究纳入FIGO III-IV期卵巢癌计划行间歇性CRS患者,评估MRI-derived PCI(mriPCI)预测完全CRS的诊断性能。194例可分析,完全CRS率77%,mriPCI预测完全CRS的AUC为0.76,术中披露MRI后修订sPCI的AUC为0.88,19%患者sPCI因MRI改变。结论认为MRI可无创准确预测完全间歇性CRS可行性。
要点
- mriPCI预测完全间歇性CRS的AUC为0.76,修订sPCI的AUC为0.88。
- 术中披露MRI使19%患者的手术PCI发生改变。
- mriPCI观察者间信度ICC为0.81(95%CI 0.67-0.88)。
核心结论
- MRI可无创准确预测晚期卵巢癌患者完全间歇性肿瘤细胞减灭术的可行性。
- 将MRI整合入手术规划可增强术中病灶检测并辅助决策。
研究设计与样本
- 前瞻性多中心队列研究,纳入FIGO III-IV期卵巢癌计划行间歇性CRS患者。
- 样本量计算提示需纳入189例间歇性CRS患者,实际招募270例,194例符合分析。
主要发现
- 194例中149例(77%)实现完全间歇性CRS。
- mriPCI预测完全CRS的AUC为0.76。
- 术中披露MRI后修订sPCI的AUC为0.88。
- MRI使19%患者的sPCI发生改变。
- mriPCI观察者间信度ICC为0.81(95%CI 0.67-0.88)。
关键数值与推荐
- 主要终点为mriPCI预测完全间歇性CRS(无肉眼残留病灶)的能力。
- 次要终点包括mriPCI与sPCI的一致性、MRI披露的诊断收益及观察者间一致性。
临床怎么用
- 对计划行间歇性CRS的晚期卵巢癌患者,可考虑术前MRI评估mriPCI以预测完全切除可行性。
- 术中披露MRI结果可修正手术PCI并辅助手术决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with advanced ovarian cancer, complete cytoreductive surgery (CRS) offers the best chance for long-term survival and cure. Currently, staging relies on CT and, in selected cases, diagnostic laparoscopy, both of which have important limitations. This study assessed the diagnostic performance of MRI for predicting complete interval CRS. METHODS: This prospective multicentre cohort study included FIGO stage III-IV ovarian cancer patients scheduled for interval CRS. Radiologists, blinded to surgical findings, independently scored the MRI-derived Peritoneal Cancer Index (mriPCI). Gynaecologic oncologists recorded the surgical PCI (sPCI) before and after intraoperative disclosure of MRI findings (revised-sPCI). The primary endpoint was the ability of mriPCI to predict complete interval CRS (no macroscopic residual disease). Secondary endpoints included concordance between mriPCI and sPCI, diagnostic yield from MRI disclosure, and inter-reader agreement. Sample size calculations indicated that 189 patients undergoing interval CRS should be included. RESULTS: Between 2018 and 2023, 270 patients were recruited, of whom 194 were eligible for analysis. Complete interval CRS was achieved in 149/194 patients (77%). The diagnostic performance of mriPCI showed an AUC of 0.76 for predicting a complete CRS. The revised-SPCI, after intraoperative disclosure of MRI led to an AUC of 0.88. MRI findings led to a change in sPCI in 19% of patients. Interobserver reliability for mriPCI was substantial (Interclass correlation coefficient 0.81, 95% CI 0.67-0.88). CONCLUSIONS: MRI enables accurate, non-invasive prediction of complete interval CRS feasibility in advanced ovarian cancer. Integration of MRI into surgical planning enhances intraoperative detection of lesions and can facilitate decision-making, supporting its role as a non-invasive staging tool. TRIAL REGISTRATION NUMBER: NCT03399344.
引用
- Berardi E, J van Driel W, H M Hermans R, et al. MRI in advanced ovarian cancer: multicentre MISSION trial. Eur J Cancer. 2026. PMID: 41780181. doi:10.1016/j.ejca.2026.116614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。